By contrast, PRIMO-FRL explicitly optimizes multiple clinical goals, including hypoglycemia prevention, glucose stability, and insulin efficiency, making it better suited for real-world applications where trade-offs between multiple factors are necessary. This evidence concerns the gene INS and Hypoglycemia.